Terms: = Endocrine gland cancer AND PTPN11, CFC, Q06124, 5781, ENSG00000179295, SHP2, MGC14433, SHP-2, BPTP3, PTP-1D, SH-PTP3, NS1, SH-PTP2, PTP2C AND Treatment
23 results:
1. Identification of a Novel, Potent, and Orally Bioavailable Guanidine-Based shp2 Allosteric Inhibitor from Virtual Screening and Rational Structural Optimization for the treatment of KRAS Mutant cancers.
Hou Q; Jiang W; Li W; Huang C; Yang K; Chen X; Huang M; Shu C; Luo G; Sun H; Chu Q; Wu X
J Med Chem; 2023 Oct; 66(19):13646-13664. PubMed ID: 37754066
[TBL] [Abstract] [Full Text] [Related]
2. Disruption of Ovarian cancer STAT3 and p38 Signaling with a Small-Molecule Inhibitor of PTP4A3 Phosphatase.
Lazo JS; Isbell KN; Vasa SA; Llaneza DC; Rastelli EJ; Wipf P; Sharlow ER
J Pharmacol Exp Ther; 2023 Mar; 384(3):429-438. PubMed ID: 36627205
[TBL] [Abstract] [Full Text] [Related]
3. Drug response profiles in patient-derived cancer cells across histological subtypes of ovarian cancer: real-time therapy tailoring for a patient with low-grade serous carcinoma.
Murumägi A; Ungureanu D; Khan S; Arjama M; Välimäki K; Ianevski A; Ianevski P; Bergström R; Dini A; Kanerva A; Koivisto-Korander R; Tapper J; Lassus H; Loukovaara M; Mägi A; Hirasawa A; Aoki D; Pietiäinen V; Pellinen T; Bützow R; Aittokallio T; Kallioniemi O
Br J Cancer; 2023 Feb; 128(4):678-690. PubMed ID: 36476658
[TBL] [Abstract] [Full Text] [Related]
4. Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Oba T; Chino T; Soma A; Shimizu T; Ono M; Ito T; Kanai T; Maeno K; Ito KI
Endocr J; 2020 Dec; 67(12):1215-1226. PubMed ID: 32814730
[TBL] [Abstract] [Full Text] [Related]
5. ptpn11 Knockdown Prevents Changes in the Expression of Genes Controlling Cell Cycle, Chemotherapy Resistance, and Oncogene-Induced Senescence in Human Thyroid Cells Overexpressing BRAF V600E Oncogenic Protein.
Putlyaeva LV; Demin DE; Uvarova AN; Zinevich LS; Prokofjeva MM; Gazizova GR; Shagimardanova EI; Schwartz AM
Biochemistry (Mosc); 2020 Jan; 85(1):108-118. PubMed ID: 32079522
[TBL] [Abstract] [Full Text] [Related]
6. Tyrosyl phosphorylation of KRAS stalls GTPase cycle via alteration of switch I and II conformation.
Kano Y; Gebregiworgis T; Marshall CB; Radulovich N; Poon BPK; St-Germain J; Cook JD; Valencia-Sama I; Grant BMM; Herrera SG; Miao J; Raught B; Irwin MS; Lee JE; Yeh JJ; Zhang ZY; Tsao MS; Ikura M; Ohh M
Nat Commun; 2019 Jan; 10(1):224. PubMed ID: 30644389
[TBL] [Abstract] [Full Text] [Related]
7. Clinicopathological and prognostic significance of shp2 and Hook1 expression in patients with thyroid carcinoma.
Cao J; Huang YQ; Jiao-Sun ; Lan XB; Ge MH
Hum Pathol; 2018 Nov; 81():105-112. PubMed ID: 29953894
[TBL] [Abstract] [Full Text] [Related]
8. EGFL6 Regulates the Asymmetric Division, Maintenance, and Metastasis of ALDH+ Ovarian cancer Cells.
Bai S; Ingram P; Chen YC; Deng N; Pearson A; Niknafs YS; O'Hayer P; Wang Y; Zhang ZY; Boscolo E; Bischoff J; Yoon E; Buckanovich RJ
Cancer Res; 2016 Nov; 76(21):6396-6409. PubMed ID: 27803106
[TBL] [Abstract] [Full Text] [Related]
9. An engineered avian-origin influenza A virus for pancreatic ductal adenocarcinoma virotherapy.
Pizzuto MS; Silic-Benussi M; Ciminale V; Elderfield RA; Capua I; Barclay WS
J Gen Virol; 2016 Sep; 97(9):2166-2179. PubMed ID: 27417501
[TBL] [Abstract] [Full Text] [Related]
10. HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer.
Fan G; Zhang S; Gao Y; Greer PA; Tonks NK
Genes Dev; 2016 Jul; 30(13):1542-57. PubMed ID: 27401557
[TBL] [Abstract] [Full Text] [Related]
11. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
[TBL] [Abstract] [Full Text] [Related]
12. Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for treatment of Pancreatic Adenocarcinoma.
Buijs P; van Nieuwkoop S; Vaes V; Fouchier R; van Eijck C; van den Hoogen B
Viruses; 2015 Jun; 7(6):2980-98. PubMed ID: 26110582
[TBL] [Abstract] [Full Text] [Related]
13. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract] [Full Text] [Related]
14. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
Li J; Bonifati S; Hristov G; Marttila T; Valmary-Degano S; Stanzel S; Schnölzer M; Mougin C; Aprahamian M; Grekova SP; Raykov Z; Rommelaere J; Marchini A
EMBO Mol Med; 2013 Oct; 5(10):1537-55. PubMed ID: 24092664
[TBL] [Abstract] [Full Text] [Related]
15. Oncosuppressive suicide gene virotherapy "PVH1-yCD/5-FC" for pancreatic peritoneal carcinomatosis treatment: NFκB and Akt/PI3K involvement.
Réjiba S; Bigand C; Parmentier C; Masmoudi A; Hajri A
PLoS One; 2013; 8(8):e70594. PubMed ID: 23967078
[TBL] [Abstract] [Full Text] [Related]
16. A rare case of Hodkin's lymphoma of the mediastinum imitating retrosternal goiter--retrospective analysis of the diagnostic process.
Dedecjus M; Kędzierska A; Kozak J; Kordek R; Brzeziński J
Pol Przegl Chir; 2012 Jul; 84(7):363-6. PubMed ID: 22935459
[TBL] [Abstract] [Full Text] [Related]
17. Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.
Connelly SF; Isley BA; Baker CH; Gallick GE; Summy JM
Mol Carcinog; 2010 Dec; 49(12):1007-21. PubMed ID: 20945416
[TBL] [Abstract] [Full Text] [Related]
18. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells.
Saydmohammed M; Joseph D; Syed V
J Cell Biochem; 2010 May; 110(2):447-56. PubMed ID: 20235152
[TBL] [Abstract] [Full Text] [Related]
19. Small-molecule inhibitor of the AP endonuclease 1/REF-1 E3330 inhibits pancreatic cancer cell growth and migration.
Zou GM; Maitra A
Mol Cancer Ther; 2008 Jul; 7(7):2012-21. PubMed ID: 18645011
[TBL] [Abstract] [Full Text] [Related]
20. Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243).
Sessa C; Zucchetti M; Ghielmini M; Bauer J; D'Incalci M; de Jong J; Naegele H; Rossi S; Pacciarini MA; Domenigoni L; Cavalli F
Cancer Chemother Pharmacol; 1999; 44(5):403-10. PubMed ID: 10501914
[TBL] [Abstract] [Full Text] [Related]
[Next]
